TY - JOUR T1 - Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial JF - BMJ Open Gastroenterology DO - 10.1136/bmjgast-2017-000194 VL - 5 IS - 1 SP - e000194 AU - Kazunori Yoh AU - Hiroki Nishikawa AU - Hirayuki Enomoto AU - Noriko Ishii AU - Yoshinori Iwata AU - Akio Ishii AU - Yukihisa Yuri AU - Yuho Miyamoto AU - Kunihiro Hasegawa AU - Chikage Nakano AU - Ryo Takata AU - Takashi Nishimura AU - Nobuhiro Aizawa AU - Yoshiyuki Sakai AU - Naoto Ikeda AU - Tomoyuki Takashima AU - Hiroko Iijima AU - Shuhei Nishiguchi Y1 - 2018/02/01 UR - http://bmjopengastro.bmj.com//content/5/1/e000194.abstract N2 - Introduction and purpose Sarcopenia is defined as a decrease in muscle mass and muscle strength, and it has been demonstrated to be an adverse predictor in numerous types of cancers. Exercise therapy (ET) carries multiple health benefits in several diseases. Despite these clinical benefits, there are limited data available regarding patients with pancreatic cancer (PC) undergoing ET. We aim to prospectively examine the effect of ET on sarcopenia in patients with PC.Methods and analysis All clinical stages of PC can be included. When registering study subjects, a precise evaluation of the nutritional status and the daily physical activities performed will be undertaken individually, for each participant. Study participants will be randomly allocated into two groups: (1) the ET and standard therapy group and (2) the standard therapy group. Amelioration of sarcopenia at 3 months postrandomisation will be the primary endpoint. Muscle mass will be calculated using bioimpedance analysis. Sarcopenia will be defined based on the current Asian guidelines. Participants will be instructed to perform exercises with > 3 metabolic equivalents (mets; energy consumption in physical activities/resting metabolic rate) for 60 min/day and to perform exercises with > 23 mets/week. In the ET group, physical activities equal to or greater than walking for 60 min/day will be strongly recommended.Ethics and dissemination The Institutional Review Board at Hyogo College of Medicine has approved this study protocol (approval no. 2772). The final data will be publicly announced. A report releasing the study results will be submitted for publication.Trial registration number UMIN000029271; Pre-results. ER -